Loading...
XSHE
300363
Market cap1.80bUSD
Dec 05, Last price  
23.42CNY
1D
1.25%
1Q
-9.58%
Jan 2017
16.81%
IPO
120.83%
Name

Porton Pharma Solutions Ltd

Chart & Performance

D1W1MN
XSHE:300363 chart
P/E
P/S
4.23
EPS
Div Yield, %
2.08%
Shrs. gr., 5y
0.32%
Rev. gr., 5y
14.19%
Revenues
3.01b
-17.87%
288,537,016455,834,356552,566,462689,879,030734,360,858987,255,9051,021,209,2211,326,634,0321,184,088,7671,184,863,2561,551,298,7622,071,875,4213,105,149,6297,034,801,0543,667,417,1213,011,966,354
Net income
-288m
L
30,234,06543,049,63262,395,12380,274,464100,201,387125,486,041110,394,837171,189,670107,449,932124,494,102185,550,375324,416,211523,915,3832,005,442,175266,859,527-287,753,297
CFO
406m
-35.53%
31,986,84635,753,79065,428,148114,209,604114,053,198121,921,427112,313,252285,331,010289,458,495193,617,828351,373,889504,374,812480,173,0872,564,418,941629,056,261405,525,823
Dividend
May 29, 20240.487 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Porton Pharma Solutions Ltd. manufactures and supplies small molecule active pharmaceutical ingredients and drug intermediates, dosage forms, and biologics to the pharmaceutical companies. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. Porton Pharma Solutions Ltd. was founded in 2005 and is headquartered in Chongqing, China.
IPO date
Jan 29, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT